Mylan Brovana Patent Trial Against Sunovion Set for May 21
This article is for subscribers only.
Mylan Inc.’s patent infringement trial against Sunovion Pharmaceuticals Inc. over the bronchitis and emphysema drug Brovana was set for May 21.
U.S. District Judge John Koeltl set the date today at a hearing in Manhattan, saying he would also refer the case to a magistrate judge for settlement talks. On March 1, Koeltl invalidated five of the seven patents Canonsburg, Pennsylvania-based Mylan said were infringed and limited damages that could be assessed on the other two.